Terazosin (Vicard®) is an alpha receptor activator that increases blood flow to the prostate. As a side effect, a significant improvement in ATP production (energy) in the brain was now found. This was noticed because Parkinson’s patients with prostate problems and Vicard medication had much better outcomes. Preclinical studies of terazosin in Parkinson’s disease were successful.
Maybe this drug can even be used in degenerative disorders to improve blood circulation?
We would then have Trazodone (Trittico®) as another repurposed drug for causal treatment of neurodegenerative diseases
only 700 studies in Google Scholar on this Topic, all brand new and successful across the board!
Here 2 typical studies translated and summarized
A pilot project to assess the target effect of terazosin in Parkinson’s disease
Summary by Dr. Retzek
It happened by chance that Parkinson’s patients who received terazosin as a prostate medication had a much better outcome – while tamsulosin patients had increased rates of Parkinson’s and Alzheimer’s disease.
A randomized double-blind study with Parkinson’s patients taking terazosin is being carried out (highest level of validity) to see that the known in vitro effect of terazosin: the increase of ATP in the nerve cells is actually present in vivo.
Side effects were a reduction in blood pressure due to the expansion of blood vessels (dizziness).
Result: much more ENERGY was detected in the brains of affected patients, and the ATP content was also increased directly in the blood
Conclusion: it actually works, you get a direct causal therapy – unlike L-Dopa which is only symptomatic!
Second study – Tamsulosin increases the risk of Parkinson’s, terazosin improves it
Tamsulosin = Alna retard®, Aglandin®, Tamsu®, Dutaglandin®,
Terazosin improves mitochondria in Parkinson’s patients. Studies show that taking the drug (for the prostate or heart) reduces the risk of Parkinson’s disease compared to tamsulosin users.
Meanwhile I found another study that describes
t that tamsulosin also increases Alzheimer’s dementia
Almost 115,000 patients are now being examined here, Parkinson’s occurs in 1.5% of the tamsulosin patients, only in 1% of the terazosin patients as well as in 1% of the “control patients”.
Conclusion: Terazosin and similar agents do not increase the risk of Parkinson’s disease, but neither do they reduce it compared to the control group. Tamsulosin patients have a minimal risk increase of 0.5% (I would ignore that).